Exercise Can Help Childhood Hodgkin's Survivors Avoid Heart Problems

Researchers found that the incidence of cardiovascular events was higher among Hodgkin's survivors who do not exercise compared with those that do.

Using questionnaires to evaluate exercise behavior and occurrence of cardiovascular events in 1,187 adult survivors of Hodgkin's lymphoma, Lee W. Jones, Ph.D., of the Memorial Sloan Kettering Cancer Center and colleagues found that over a median follow-up time of 11.9 years, the cumulative incidence of any cardiovascular event at ten years was higher among cancer survivors reporting zero metabolic equivalent (MET) hours/week−1 of vigorous-intensity exercise (12.2 percent) than those reporting ≥ 9 MET hours/week−1 (5.2 percent).

Compared with cancer survivors who did not meet the guidelines for ≥ 9 MET hours/week−1 of vigorous-intensity exercise, those who met the guidelines had a 51 percent reduction in the risk of any cardiovascular event.

"Vigorous exercise was associated with a lower risk of cardiovascular events in a dose-dependent manner independent of cardiovascular risk profile and treatment in survivors of Hodgkin lymphoma," the authors concluded.

The team reported its findings in the Journal of Clinical Oncology.

Source: Medicalxpress

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap